Marek K - Search Results

1

¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy.

Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann KT, Rauchmann BS, Rullmann M, Marek K, Villemagne VL, Rumpf JJ, Saur D, Schroeter ML, Schildan A, Patt M, Beyer L, Song M, Palleis C, Katzdobler S, Fietzek UM, Respondek G, Scheifele M, Nitschmann A, Zach C, Barret O, Madonia J, Russell D, Stephens AW, Koglin N, Roeber S, Herms J, Bötzel K, Bartenstein P, Levin J, Seibyl JP, Höglinger G, Classen J, Sabri O; German Imaging Initiative for Tauopathies (GII4T). Messerschmidt K, et al. Among authors: marek k. J Nucl Med. 2022 Nov;63(11):1754-1760. doi: 10.2967/jnumed.121.262854. Epub 2022 Apr 14. J Nucl Med. 2022. PMID: 35422444 Free PMC article.

2

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP. Innis RB, et al. Among authors: marek kl. Mov Disord. 1999 May;14(3):436-42. doi: 10.1002/1531-8257(199905)14:3<436::aid-mds1008>3.0.co;2-j. Mov Disord. 1999. PMID: 10348466 Clinical Trial.

3

[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.

Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. Varrone A, et al. Among authors: marek kl. Mov Disord. 2001 Nov;16(6):1023-32. doi: 10.1002/mds.1256. Mov Disord. 2001. PMID: 11748733

4

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.

Marek K, Jennings D, Seibyl J. Marek K, et al. Adv Neurol. 2003;91:183-91. Adv Neurol. 2003. PMID: 12442677 Review. No abstract available.

5

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.

Marek K, Jennings D, Seibyl J. Marek K, et al. Ann Neurol. 2003;53 Suppl 3:S160-6; discussion S166-9. doi: 10.1002/ana.10486. Ann Neurol. 2003. PMID: 12666107 Review. No abstract available.

6

Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.

Marek K, Jennings D, Seibyl J. Marek K, et al. Neurology. 2003 Sep 23;61(6 Suppl 3):S43-8. doi: 10.1212/wnl.61.6_suppl_3.s43. Neurology. 2003. PMID: 14504379 Review. No abstract available.

7

Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients.

Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Zubal IG, et al. Among authors: marek k. J Nucl Med. 2007 Jun;48(6):857-64. doi: 10.2967/jnumed.106.037432. Epub 2007 May 15. J Nucl Med. 2007. PMID: 17504864 Free article.

8

Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.

Marek K, Jennings D, Tamagnan G, Seibyl J. Marek K, et al. Ann Neurol. 2008 Dec;64 Suppl 2:S111-21. doi: 10.1002/ana.21602. Ann Neurol. 2008. PMID: 19127587

9

The role of the core imaging laboratory in multicenter trials.

Seibyl J, Marek K, Zubal IG. Seibyl J, et al. Among authors: marek k. Semin Nucl Med. 2010 Sep;40(5):338-46. doi: 10.1053/j.semnuclmed.2010.03.002. Semin Nucl Med. 2010. PMID: 20674593

10

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators. Schwarzschild MA, et al. Among authors: marek k. Mov Disord. 2011 Aug 15;26(10):1864-8. doi: 10.1002/mds.23741. Epub 2011 Apr 29. Mov Disord. 2011. PMID: 21538532 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

453 results

Search Page

Filters